NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
STIMNeuronetics(STIM) GlobeNewswire News Room·2024-10-14 20:31

MALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the American Academy of Child and Adolescent Psychiatry (AACAP) in Seattle, WA, from October 14th-19th, including an oral presentation at the "Research Pipeline: New Findings on Therapeutics" session featuring data gener ...